Clinical trial NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Official title: A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: SCLC,Extensive Stage
SLFN11-positive
Lead sponsor: ETOP IBCSG Partners Foundation
Sponsor class: NETWORK
Collaborators: name: GlaxoSmithKline
name: Development Limited
First posted: 2023-02-08
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.


Eligibility criteria: Inclusion Criteria:

Inclusion criteria for SLFN11-expression testing

* Written IC part 1: for SLFN11-screening must be signed and dated by the patient and the investigator prior to sending any tumour material to the central laboratory.
* Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification).
* Availability of FFPE tumour tissue for screening.

Inclusion criteria for trial participation

* Written IC part 2: for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention.
* High SLFN11-expression on FFPE tumour material:

SLFN11-expression is determined at the central screening laboratory in Basel. Overexpression is defined as detectable protein expression by IHC in ≥20% of tumour cells.

* Patients must have received standard first-line chemo-immunotherapy, consisting of 4 cycles of platinum-etoposide chemotherapy in combination with an anti-PD-L1 antibody (atezolizumab or durvalumab). Patients who started the immunotherapy at chemotherapy cycle 2 are eligible.
* ED-SCLC must not have progressed during or after standard chemo-immunotherapy (as per RECIST v1.1).
* Patients must be candidates for ongoing maintenance treatment with immune-checkpoint inhibition.
* Adequate haematological function:
* Adequate renal function:
* Adequate liver function:
* ECOG PS 0-2
* Age ≥18 years
* Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 4 weeks before enrolment and within 3 days before treatment start.

Exclusion Criteria:

* Symptomatic brain metastases
* Any clinically active cancer, other than SCLC Exception: malignancies with negligible risk of metastases or death (e.g. 5-year OS rate of \>90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer. Hormonal therapy for non-metastatic prostate or ductal carcinoma in situ is allowed.

Consolidating thoracic radiotherapy. Palliative radiotherapy to the brain or to bones is allowed.

* History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
* Any lung disease requiring systemic steroids in doses of \>10 mg prednisolone (or equivalent dose of other steroid).
* Any serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) which in the opinion of the investigator would compromise the patient's ability to complete the trial or interfere with the evaluation of the efficacy and safety of the protocol treatment.
* Inadequately controlled hypertension, defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>95 mmHg.

The patient must be considered stable and hypertension medically controlled.

* History of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).
* Prior Reversible Encephalopathy Syndrome (PRES)
* Severe renal or hepatic impairment.
* Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
* Treated with live vaccine within 30 days before enrolment.
* Hypersensitivity to niraparib or any of its excipients (e.g., tartrazine).
* Women who are pregnant or in the period of lactation.
* Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the trial and within the required timelines after last dose of niraparib treatment.
* Judgment by the investigator that the patient is unlikely to comply with trial procedures, restrictions and requirements.

Primary outcomes:
measure: Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1)
timeFrame: From date of enrolment until 3 months post-enrolment
Secondary outcomes:
measure: Progression-free survival (PFS)
timeFrame: From the date of enrolment until last tumour assessment (approximately 25-30 months after the enrolment of the first patient)
measure: Overall survival (OS)
timeFrame: From the date of enrolment until death from any cause (approximately 25-30 months after the enrolment of the first patient)
measure: Disease control rate (DCR) by investigator assessment (according to RECIST v1.1)
timeFrame: approximately 25-30 months after the enrolment of the first patient
measure: Adverse events according to CTCAE v5.0
timeFrame: From the date of enrolment until last patient last visit (approximately 25- 30 months after enrolment of the first patient)
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU - Angers
city: Avignon
country: France
facility: Centre Hospitalier d'Avignon
city: Caen
country: France
facility: Caen - CHU
city: Lyon
country: France
facility: Lyon - Centre Léon Bérard
city: Meldola
country: Italy
facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
city: Milan
country: Italy
facility: Instituto Europeo di Oncologia (IEO)
city: Perugia
country: Italy
facility: Santa Maria della Misericordia Hospital
city: Treviso
country: Italy
facility: AULSS2 Marca Trevigiana Treviso
city: A Coruña
country: Spain
facility: Complejo Hospitalario Universitario a Coruña
city: Jaén
country: Spain
facility: Complejo Hospitalario de Jaén
city: Madrid
country: Spain
facility: Hospital Universitario Puerta de Hierro
city: Baden
country: Switzerland
facility: Kantonsspital Baden
city: Basel
country: Switzerland
facility: University Hospital Basel
city: Bern
country: Switzerland
facility: Inselspital Bern
city: Saint Gallen
country: Switzerland
facility: Kantonsspital St. Gallen
city: Sion
country: Switzerland
facility: Centre Hospitalier du Valais Romand
city: Solothurn
country: Switzerland
facility: Bürgerspital Solothurn
city: Winterthur
country: Switzerland
facility: Kantonsspital Winterthur
Study officials:
affiliation: Department of Medical Oncology, Cantonal Hospital St.Gallen
name: Markus Joerger, MD-PhD
role: STUDY_CHAIR
References: